Lipid-lowering drugs affect lung cancer risk via sphingolipid metabolism: a drug-target Mendelian randomization study

Background: The causal relationship between lipid-lowering drug (LLD) use and lung cancer risk is controversial, and the role of sphingolipid metabolism in this effect remains unclear. Methods: Genome-wide association study data on low-density lipoprotein (LDL), apolipoprotein B (ApoB), and triglyce...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Honglin, Zhang, Lei, Yang, Feiran, Feng, Xiaoteng, Fu, Rong, Zhao, Ruohan, Li, Xiurong, Li, Huijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687161/
https://www.ncbi.nlm.nih.gov/pubmed/38034491
http://dx.doi.org/10.3389/fgene.2023.1269291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687161/
https://www.ncbi.nlm.nih.gov/pubmed/38034491
http://dx.doi.org/10.3389/fgene.2023.1269291

Ejemplares similares